Vemurafenib FDA approved for treatment of Erdheim-Chester Disease with BRAF V600 mutation

Non-Sponsored Content

By: scienterrific | Last updated: 6 November 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

vemurafenib, Genentech, BRAF, ECD, Erdheim-Chester Disease, V600, Zelboraf, Roche, FDA

On 6 November 2017, the FDA granted regular approval to vemurafenib (Zelboraf®, Roche) for the treatment of patients with Erdheim-Chester Disease (ECD) harbouring a BRAF V600 mutation.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content